Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12739093 | 0.94 | CYP1A1 (0.38) | OPRL1FFAR1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12734152 | 0.92 | OPRL1 (0.32) | OPRL1 | |
| SCHEMBL12734141 | 0.89 | CYP1A2 (0.35) | OPRL1FFAR1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12734020 | 0.86 | MAPT (0.31) | — | |
| SCHEMBL12738982 | 0.86 | MAPT (0.31) | — | |
| SCHEMBL12734161 | 0.86 | FFAR1 (0.35) | OPRL1FFAR1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12739107 | 0.86 | KDM4E (0.31) | — | |
| SCHEMBL10301833 | 0.86 | HTR2A (0.35) | CYP1A1CYP1A2CYP1B1HTR2A | |
| SCHEMBL19722481 | 0.85 | OPRL1 (0.41) | OPRL1FFAR1HTR2A | |
| SCHEMBL12734148 | 0.85 | OPRL1 (0.33) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | OPRL1 2073/4885FFAR1 247/4885CYP1A1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.